Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
22.79
-0.64 (-2.73%)
Aug 31, 2026, 12:42 PM EDT - Market open
Bicara Therapeutics Stock Forecast
Stock Price Forecast
According to 16 analysts polled by S&P Global, Bicara Therapeutics stock has a consensus rating of "Buy" and an average price target of $33.5. The average 1-year stock price forecast is 46.99% higher than the current stock price, while the lowest is $20 (-12.24%) and the highest is $45 (+97.46%).
Price Target: $33.5 (+46.99%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Bicara Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 9 | 9 | 9 | 9 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 15 | 15 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst BMO Capital No rating | BMO Capital | Buy Initiates $35 | Buy | Initiates | $35 | +53.58% | Aug 18, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $45 | Buy | Maintains | $45 | +97.46% | Aug 14, 2026 |
Unknown Analyst Wedbush No rating | Wedbush | Buy Maintains $33 | Buy | Maintains | $33 | +44.80% | Aug 13, 2026 |
| Mizuho Securities | Mizuho Securities | Hold Maintains $20 | Hold | Maintains | $20 | -12.24% | Aug 13, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $39 → $37 | Buy | Maintains | $39 → $37 | +62.35% | Aug 12, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.36
from -2.52
EPS Next Year
-3.44
from -3.36
EPS and Forward PE are based on non-GAAP adjusted numbers.